Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COGNITION-GUIDE
2024-514022-23-00Phase 2Authorised
- Sponsor
- German Cancer Research Center
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab, ipatasertib, trastuzumab, pertuzumab, olaparib and 2 more in breast cancer (6 cohorts), sponsored by German Cancer Research Center. Primary endpoint: Invasive disease-free survival at 4 years after surgery. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-514022-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514022-23-00.